Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.87
TBPH's Cash-to-Debt is ranked lower than
75% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. TBPH: 1.87 )
Ranked among companies with meaningful Cash-to-Debt only.
TBPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.5  Med: No Debt Max: No Debt
Current: 1.87
1.5
No Debt
Equity-to-Asset 0.13
TBPH's Equity-to-Asset is ranked lower than
86% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TBPH: 0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
TBPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.69  Med: 0.81 Max: 0.89
Current: 0.13
-0.69
0.89
Debt-to-Equity 3.53
TBPH's Debt-to-Equity is ranked lower than
93% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. TBPH: 3.53 )
Ranked among companies with meaningful Debt-to-Equity only.
TBPH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.64  Med: 1.07 Max: 3.53
Current: 3.53
0.64
3.53
Debt-to-EBITDA -0.85
TBPH's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. TBPH: -0.85 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TBPH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.27  Med: -1.06 Max: -0.85
Current: -0.85
-1.27
-0.85
Piotroski F-Score: 3
Altman Z-Score: -1.39
Beneish M-Score: -3.55
WACC vs ROIC
10.59%
-865.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -1291.44
TBPH's Operating Margin % is ranked lower than
81% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. TBPH: -1291.44 )
Ranked among companies with meaningful Operating Margin % only.
TBPH' s Operating Margin % Range Over the Past 10 Years
Min: -69152.21  Med: -1061.23 Max: -7.36
Current: -1291.44
-69152.21
-7.36
Net Margin % -1383.13
TBPH's Net Margin % is ranked lower than
82% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. TBPH: -1383.13 )
Ranked among companies with meaningful Net Margin % only.
TBPH' s Net Margin % Range Over the Past 10 Years
Min: -69152.21  Med: -1143.77 Max: -7.36
Current: -1383.13
-69152.21
-7.36
ROE % -158.82
TBPH's ROE % is ranked lower than
80% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. TBPH: -158.82 )
Ranked among companies with meaningful ROE % only.
TBPH' s ROE % Range Over the Past 10 Years
Min: -173.81  Med: -95.52 Max: -64.27
Current: -158.82
-173.81
-64.27
ROA % -56.15
TBPH's ROA % is ranked lower than
63% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. TBPH: -56.15 )
Ranked among companies with meaningful ROA % only.
TBPH' s ROA % Range Over the Past 10 Years
Min: -1241.48  Med: -57.13 Max: -40.6
Current: -56.15
-1241.48
-40.6
ROC (Joel Greenblatt) % -2912.75
TBPH's ROC (Joel Greenblatt) % is ranked lower than
75% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. TBPH: -2912.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TBPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3053.02  Med: -2318.22 Max: -1855.73
Current: -2912.75
-3053.02
-1855.73
3-Year Revenue Growth Rate -7.20
TBPH's 3-Year Revenue Growth Rate is ranked lower than
64% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. TBPH: -7.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TBPH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.6  Med: -7.2 Max: 437.7
Current: -7.2
-32.6
437.7
3-Year EBITDA Growth Rate 11.60
TBPH's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. TBPH: 11.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TBPH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -198.6  Med: 6.1 Max: 11.6
Current: 11.6
-198.6
11.6
3-Year EPS without NRI Growth Rate 9.90
TBPH's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. TBPH: 9.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TBPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.9
Current: 9.9
0
9.9
GuruFocus has detected 4 Warning Signs with Theravance Biopharma Inc TBPH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TBPH's 30-Y Financials

Financials (Next Earnings Date: 2018-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

TBPH Guru Trades in Q2 2017

Seth Klarman 9,273,991 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 93,300 sh (-9.68%)
» More
Q3 2017

TBPH Guru Trades in Q3 2017

Seth Klarman 9,309,168 sh (+0.38%)
Chuck Royce 93,300 sh (unchged)
» More
Q4 2017

TBPH Guru Trades in Q4 2017

Pioneer Investments 1,500 sh (New)
Seth Klarman 9,309,168 sh (unchged)
Chuck Royce 93,300 sh (unchged)
» More
Q1 2018

TBPH Guru Trades in Q1 2018

Jim Simons 40,300 sh (New)
Seth Klarman 9,309,168 sh (unchged)
Chuck Royce 93,300 sh (unchged)
Pioneer Investments Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TBPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2017-09-30 Add 0.38%0.02%$23.88 - $42.56 $ 25.83-21%9,309,168
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Theravance Biopharma Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:XNCR, SZSE:002275, XSWX:SFZN, NAS:PRTA, NAS:RGEN, NAS:PTCT, NAS:ICPT, NAS:IOVA, TSE:4565, NAS:ATRA, SHSE:600645, NAS:ENTA, OCSE:ALK B, NAS:EPZM, TSE:4592, SZSE:002030, OSTO:VITR, SZSE:000403, NAS:IMGN, NAS:APLS » details
Traded in other countries:0TB.Germany,
Headquarter Location:Cayman Islands
Theravance Biopharma Inc is a diversified biopharmaceutical company. It is engaged in discovery, research, development and commercialization of human therapeutics.

Theravance Biopharma is a diversified biotechnology company that creates medicines to treat serious illnesses. The company's research and development are concentrated primarily on four therapeutic areas-infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease. Its commercial infrastructure is focused primarily on the acute care setting. The company uses strategic collaboration with other industry players. Theravance generates the majority of its revenue in the U.S. and Europe, followed by Asia.

Top Ranked Articles about Theravance Biopharma Inc

Theravance Biopharma Highlights Submission of Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD
Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension
Theravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018
Seth Klarman Dives Into Orexigen in Wake of Sale Beleaguered pharmaceutical company is being acquired for $75 million
Baupost Group’s Seth Klarman (Trades, Portfolio) disclosed this week he plunged into floundering pharmaceutical company Orexigen Therapeutics Inc. (OREX) on April 13, buying over 7 million shares. Read more...
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference

Ratios

vs
industry
vs
history
PB Ratio 22.35
TBPH's PB Ratio is ranked lower than
85% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. TBPH: 22.35 )
Ranked among companies with meaningful PB Ratio only.
TBPH' s PB Ratio Range Over the Past 10 Years
Min: 1.5  Med: 3.61 Max: 25.05
Current: 22.35
1.5
25.05
PS Ratio 66.41
TBPH's PS Ratio is ranked lower than
82% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TBPH: 66.41 )
Ranked among companies with meaningful PS Ratio only.
TBPH' s PS Ratio Range Over the Past 10 Years
Min: 10.34  Med: 38.34 Max: 266.59
Current: 66.41
10.34
266.59
EV-to-EBIT -4.59
TBPH's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. TBPH: -4.59 )
Ranked among companies with meaningful EV-to-EBIT only.
TBPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.8  Med: -3.9 Max: -0.8
Current: -4.59
-9.8
-0.8
EV-to-EBITDA -4.65
TBPH's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. TBPH: -4.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
TBPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10  Med: -3.9 Max: -0.8
Current: -4.65
-10
-0.8
EV-to-Revenue 59.28
TBPH's EV-to-Revenue is ranked lower than
77% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. TBPH: 59.28 )
Ranked among companies with meaningful EV-to-Revenue only.
TBPH' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.3  Med: 26.9 Max: 180.5
Current: 59.28
5.3
180.5
Current Ratio 4.25
TBPH's Current Ratio is ranked higher than
64% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. TBPH: 4.25 )
Ranked among companies with meaningful Current Ratio only.
TBPH' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 6.77 Max: 10.73
Current: 4.25
0.38
10.73
Quick Ratio 4.08
TBPH's Quick Ratio is ranked higher than
64% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. TBPH: 4.08 )
Ranked among companies with meaningful Quick Ratio only.
TBPH' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 6.55 Max: 10.48
Current: 4.08
0.1
10.48
Days Inventory 866.18
TBPH's Days Inventory is ranked lower than
98% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. TBPH: 866.18 )
Ranked among companies with meaningful Days Inventory only.
TBPH' s Days Inventory Range Over the Past 10 Years
Min: 866.18  Med: 957.98 Max: 1401.54
Current: 866.18
866.18
1401.54
Days Sales Outstanding 34.93
TBPH's Days Sales Outstanding is ranked higher than
59% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. TBPH: 34.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
TBPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.85  Med: 16.65 Max: 321.39
Current: 34.93
4.85
321.39
Days Payable 295.03
TBPH's Days Payable is ranked higher than
91% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. TBPH: 295.03 )
Ranked among companies with meaningful Days Payable only.
TBPH' s Days Payable Range Over the Past 10 Years
Min: 218.57  Med: 625.47 Max: 1473.79
Current: 295.03
218.57
1473.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.10
TBPH's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. TBPH: -19.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TBPH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.1  Med: -17.9 Max: -5.6
Current: -19.1
-19.1
-5.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 861.00
TBPH's Price-to-Net-Cash is ranked lower than
93% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. TBPH: 861.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TBPH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.32  Med: 5.88 Max: 876.67
Current: 861
2.32
876.67
Price-to-Net-Current-Asset-Value 46.96
TBPH's Price-to-Net-Current-Asset-Value is ranked lower than
87% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. TBPH: 46.96 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TBPH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.83  Med: 4.29 Max: 47.82
Current: 46.96
1.83
47.82
Price-to-Tangible-Book 22.27
TBPH's Price-to-Tangible-Book is ranked lower than
78% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. TBPH: 22.27 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TBPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.66  Med: 3.33 Max: 22.7
Current: 22.27
1.66
22.7
Price-to-Median-PS-Value 1.73
TBPH's Price-to-Median-PS-Value is ranked lower than
89% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. TBPH: 1.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TBPH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 0.95 Max: 6.44
Current: 1.73
0.24
6.44
Earnings Yield (Greenblatt) % -21.92
TBPH's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. TBPH: -21.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TBPH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -123  Med: -25.7 Max: -10.2
Current: -21.92
-123
-10.2

More Statistics

Revenue (TTM) (Mil) $20.62
EPS (TTM) $ -5.41
Beta1.46
Volatility24.90%
52-Week Range $21.27 - 40.11
Shares Outstanding (Mil)54.85

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -4.50 -3.74
EPS without NRI ($) -4.50 -3.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}